Who are regional chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, docetaxel and cisplatin, PUVA (8-MOP + UVA), FLOT, Paclitaxel, Carboplatin, intrathecal chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/regional-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

regional chemotherapy — Competitive Intelligence Brief

regional chemotherapy (regional chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

regional chemotherapy (regional chemotherapy) — Delcath Systems Inc.. Regional chemotherapy involves delivering high doses of chemotherapy directly to a specific area of the body, such as the liver, to treat cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
regional chemotherapy TARGET	regional chemotherapy	Delcath Systems Inc.	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
docetaxel and cisplatin	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)
PUVA (8-MOP + UVA)	PUVA (8-MOP + UVA)	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy agent	DNA (non-specific cross-linking)
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	Queensland Centre for Gynaecological Cancer	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)
intrathecal chemotherapy	intrathecal chemotherapy	Princess Maxima Center for Pediatric Oncology	marketed	Chemotherapy administration route (intrathecal)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). regional chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/regional-chemotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab